Cargando…

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial

OBJECTIVES: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men’s strategies for copin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wade, Julia, Donovan, Jenny, Lane, Athene, Davis, Michael, Walsh, Eleanor, Neal, David, Turner, Emma, Martin, Richard, Metcalfe, Chris, Peters, Tim, Hamdy, Freddie, Kockelbergh, Roger, Catto, James, Paul, Alan, Holding, Peter, Rosario, Derek, Kynaston, Howard, Rowe, Edward, Hughes, Owen, Bollina, Prasad, Gillatt, David, Doherty, Alan, Gnanapragasam, Vincent J, Paez, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482454/
https://www.ncbi.nlm.nih.gov/pubmed/32907896
http://dx.doi.org/10.1136/bmjopen-2019-036024
_version_ 1783580790985064448
author Wade, Julia
Donovan, Jenny
Lane, Athene
Davis, Michael
Walsh, Eleanor
Neal, David
Turner, Emma
Martin, Richard
Metcalfe, Chris
Peters, Tim
Hamdy, Freddie
Kockelbergh, Roger
Catto, James
Paul, Alan
Holding, Peter
Rosario, Derek
Kynaston, Howard
Rowe, Edward
Hughes, Owen
Bollina, Prasad
Gillatt, David
Doherty, Alan
Gnanapragasam, Vincent J
Paez, Edgar
author_facet Wade, Julia
Donovan, Jenny
Lane, Athene
Davis, Michael
Walsh, Eleanor
Neal, David
Turner, Emma
Martin, Richard
Metcalfe, Chris
Peters, Tim
Hamdy, Freddie
Kockelbergh, Roger
Catto, James
Paul, Alan
Holding, Peter
Rosario, Derek
Kynaston, Howard
Rowe, Edward
Hughes, Owen
Bollina, Prasad
Gillatt, David
Doherty, Alan
Gnanapragasam, Vincent J
Paez, Edgar
author_sort Wade, Julia
collection PubMed
description OBJECTIVES: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men’s strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care. DESIGN: Longitudinal serial in-depth qualitative interviews every 2–3 years for a median 7 (range 6–14) years following diagnosis. SETTING: Four centres within the UK Protect trial. PARTICIPANTS: Purposive sample of 20 men with localised PCa: median age at diagnosis 64 years (range 52–68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8–13.8 years). INTERVENTION: AM: 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6–12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review. MAIN OUTCOMES: Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care. RESULTS: Men sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences. CONCLUSION: Men looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term. TRIAL REGISTRATION NUMBER: ISRCTN20141297; Pre-results.
format Online
Article
Text
id pubmed-7482454
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74824542020-09-18 Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial Wade, Julia Donovan, Jenny Lane, Athene Davis, Michael Walsh, Eleanor Neal, David Turner, Emma Martin, Richard Metcalfe, Chris Peters, Tim Hamdy, Freddie Kockelbergh, Roger Catto, James Paul, Alan Holding, Peter Rosario, Derek Kynaston, Howard Rowe, Edward Hughes, Owen Bollina, Prasad Gillatt, David Doherty, Alan Gnanapragasam, Vincent J Paez, Edgar BMJ Open Urology OBJECTIVES: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men’s strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care. DESIGN: Longitudinal serial in-depth qualitative interviews every 2–3 years for a median 7 (range 6–14) years following diagnosis. SETTING: Four centres within the UK Protect trial. PARTICIPANTS: Purposive sample of 20 men with localised PCa: median age at diagnosis 64 years (range 52–68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8–13.8 years). INTERVENTION: AM: 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6–12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review. MAIN OUTCOMES: Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care. RESULTS: Men sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences. CONCLUSION: Men looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term. TRIAL REGISTRATION NUMBER: ISRCTN20141297; Pre-results. BMJ Publishing Group 2020-09-09 /pmc/articles/PMC7482454/ /pubmed/32907896 http://dx.doi.org/10.1136/bmjopen-2019-036024 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Urology
Wade, Julia
Donovan, Jenny
Lane, Athene
Davis, Michael
Walsh, Eleanor
Neal, David
Turner, Emma
Martin, Richard
Metcalfe, Chris
Peters, Tim
Hamdy, Freddie
Kockelbergh, Roger
Catto, James
Paul, Alan
Holding, Peter
Rosario, Derek
Kynaston, Howard
Rowe, Edward
Hughes, Owen
Bollina, Prasad
Gillatt, David
Doherty, Alan
Gnanapragasam, Vincent J
Paez, Edgar
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title_full Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title_fullStr Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title_full_unstemmed Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title_short Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
title_sort strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the protect trial
topic Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482454/
https://www.ncbi.nlm.nih.gov/pubmed/32907896
http://dx.doi.org/10.1136/bmjopen-2019-036024
work_keys_str_mv AT wadejulia strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT donovanjenny strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT laneathene strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT davismichael strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT walsheleanor strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT nealdavid strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT turneremma strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT martinrichard strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT metcalfechris strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT peterstim strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT hamdyfreddie strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT kockelberghroger strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT cattojames strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT paulalan strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT holdingpeter strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT rosarioderek strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT kynastonhoward strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT roweedward strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT hughesowen strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT bollinaprasad strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT gillattdavid strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT dohertyalan strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT gnanapragasamvincentj strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial
AT paezedgar strategiesadoptedbymentodealwithuncertaintyandanxietywhenfollowinganactivesurveillancemonitoringprotocolforlocalisedprostatecancerandimplicationsforcarealongitudinalqualitativestudyembeddedwithintheprotecttrial